Company-reported prevalence
SKY-0515
Overview
| Field | Value |
|---|---|
| Drug | SKY-0515 |
| Indication | Huntington's disease |
| Disease | Huntington's disease |
| Company | Skyhawk Therapeutics, Inc. (privately held; no partner holding rights to SKY-0515 identified) |
| Documents searched | Corporate website home, pipeline, patients, unmet need, mission, story, platform overview, research modalities, newsroom, and media kit pages, accessed October 14, 2026; FALCON-HD trial recruitment website, accessed October 14, 2026; press releases of July 10, 2024, September 11, 2024, December 9, 2024, June 17, 2025, September 17, 2025, January 27, 2026, March 3, 2026, March 10, 2026, June 1, 2026, June 30, 2026, July 14, 2026, and September 15, 2026; media kit (company overview), October 2026; congress posters of December 2025, February 2026, and June 2026; community letter, January 26, 2026; no securities filings (privately held company) |
| Data as of | October 14, 2026 |
| Prepared by | AI research agent (Claude); not yet reviewed by a person |
Company statements of prevalence
United States
Number affected (symptomatic individuals): Skyhawk Therapeutics press release, September 2026
Cited source: None stated in the document.
(opens the full-size image in a new tab)Number affected (symptomatic patients): Skyhawk Therapeutics press release, March 2026
Number affected: Skyhawk Therapeutics press release, July 2024
Cited source: None stated in the document.
(opens the full-size image in a new tab)Europe
No evidence found.
Global
Number affected: Skyhawk Therapeutics media kit, October 2026
Cited source: None stated in the document.
(opens the full-size image in a new tab)Number affected: Skyhawk Therapeutics FALCON-HD trial website, October 2026
Cited source: None stated in the document.
(opens the full-size image in a new tab)Prevalence: Skyhawk Therapeutics FALCON-HD trial website, October 2026
Cited source: None stated in the document.
(opens the full-size image in a new tab)Number affected: Skyhawk Therapeutics press release, September 2026
Cited source: None stated in the document.
(opens the full-size image in a new tab)Number affected: Skyhawk Therapeutics press release, March 2026
Other countries and regions
Number affected (Australia): Skyhawk Therapeutics press release, March 2026
Prevalence (North America, South America, North-Western Europe, Australia, and Asia): Skyhawk Therapeutics FALCON-HD trial website, October 2026
“In North America, South America, North-Western Europe, and Australia, prevalence ranges from 6 to 14 cases per 100,000 people.”
Cited source: None stated in the document.
(opens the full-size image in a new tab)Geography not stated
No evidence found.
Sources the company cites
Australian institute of health and welfare 2025
Reference as the company lists it
Passage carrying the nearest figure
“About 2,400 Australians were estimated to be living with Huntington’s disease in 2024.”
“The meta-analysis suggests that the prevalence of Huntington’s disease is 8.9 per 100,000 population.”
Huntington's disease society of America 2026
Reference as the company lists it
References
- Australian Institute of Health and Welfare (2025) Huntington's disease in Australia (opens in a new tab)
- Huntington's Disease Society of America (2026) Overview of Huntington's Disease (opens in a new tab)
- Skyhawk Therapeutics (2024) press release, July 10, 2024 (opens in a new tab)
- Skyhawk Therapeutics (2026) FALCON-HD trial website (opens in a new tab)
- Skyhawk Therapeutics (2026) media kit, October 2026 (opens in a new tab)
- Skyhawk Therapeutics (2026) press release, March 3, 2026 (opens in a new tab)
- Skyhawk Therapeutics (2026) press release, September 15, 2026 (opens in a new tab)